Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.31 USD | +0.98% | -1.27% | -4.02% |
May. 22 | Enfusion Insider Sold Shares Worth $325,263, According to a Recent SEC Filing | MT |
May. 09 | Enfusion Shares Fall Despite Higher Q1 Results | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,373 | 667.1 | 856.3 | 855.7 | - | - |
Enterprise Value (EV) 1 | 1,309 | 604.6 | 820.7 | 801.6 | 764.5 | 722.8 |
P/E ratio | -9.27 x | -96.7 x | 139 x | 122 x | 55.3 x | 46.6 x |
Yield | - | - | - | 0.05% | - | - |
Capitalization / Revenue | 12.3 x | 4.44 x | 4.91 x | 4.17 x | 3.52 x | 3.02 x |
EV / Revenue | 11.7 x | 4.02 x | 4.7 x | 3.9 x | 3.14 x | 2.55 x |
EV / EBITDA | 57.1 x | 30.7 x | 26.1 x | 18.7 x | 13.4 x | 10 x |
EV / FCF | -157 x | 97.1 x | 51.4 x | 33.1 x | 16.9 x | - |
FCF Yield | -0.64% | 1.03% | 1.95% | 3.03% | 5.92% | - |
Price to Book | 42.8 x | 17 x | 23.1 x | 11.7 x | 7.46 x | 6.79 x |
Nbr of stocks (in thousands) | 65,583 | 68,986 | 88,280 | 91,911 | - | - |
Reference price 2 | 20.94 | 9.670 | 9.700 | 9.310 | 9.310 | 9.310 |
Announcement Date | 3/24/22 | 3/7/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 79.56 | 111.7 | 150.3 | 174.5 | 205.4 | 243.1 | 283.1 |
EBITDA 1 | - | 22.91 | 19.72 | 31.47 | 42.8 | 57.02 | 71.94 |
EBIT 1 | - | -274.7 | 13.03 | 19.41 | 31.71 | 44.72 | 57.57 |
Operating Margin | - | -245.9% | 8.67% | 11.12% | 15.44% | 18.4% | 20.34% |
Earnings before Tax (EBT) 1 | - | -281.7 | -12.19 | 11.48 | 12.36 | 24.91 | - |
Net income 1 | 4.061 | -282.2 | -13.26 | 6.025 | 12.43 | 24.71 | - |
Net margin | 5.1% | -252.68% | -8.82% | 3.45% | 6.05% | 10.16% | - |
EPS 2 | - | -2.260 | -0.1000 | 0.0700 | 0.0761 | 0.1683 | 0.1998 |
Free Cash Flow 1 | - | -8.332 | 6.225 | 15.96 | 24.25 | 45.25 | - |
FCF margin | - | -7.46% | 4.14% | 9.15% | 11.8% | 18.62% | - |
FCF Conversion (EBITDA) | - | - | 31.57% | 50.72% | 56.66% | 79.35% | - |
FCF Conversion (Net income) | - | - | - | 264.95% | 195.03% | 183.15% | - |
Dividend per Share 2 | - | - | - | - | 0.005110 | - | - |
Announcement Date | 9/17/21 | 3/24/22 | 3/7/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 31.85 | 34.14 | 36.54 | 39.15 | 40.52 | 40.97 | 42.72 | 44.36 | 46.49 | 48.05 | 49.93 | 52.34 | 55.3 | 57.06 | 59.72 |
EBITDA 1 | 3.192 | 2.088 | 5.428 | 5.435 | 6.764 | 5.703 | 7.954 | 8.028 | 9.787 | 9.179 | 9.918 | 11.05 | 12.96 | 12.23 | 13.5 |
EBIT 1 | -291.3 | 0.311 | 3.762 | 3.774 | 5.577 | 3.532 | 5.085 | 5.251 | 5.538 | 5.888 | 7.217 | 8.199 | 9.799 | 9.386 | 10.59 |
Operating Margin | -914.46% | 0.91% | 10.3% | 9.64% | 13.76% | 8.62% | 11.9% | 11.84% | 11.91% | 12.25% | 14.45% | 15.67% | 17.72% | 16.45% | 17.74% |
Earnings before Tax (EBT) 1 | -294 | -12.37 | -3.906 | 2.885 | 1.206 | 5.09 | 1.186 | 3.028 | 2.18 | -0.878 | 3.975 | 4.8 | 5.95 | 2.062 | 7.306 |
Net income 1 | -293.9 | -7.265 | -2.422 | 1.539 | 0.788 | 2.945 | 0.629 | 1.828 | 0.623 | -0.539 | 2.987 | 3.745 | 6.351 | 3.071 | 7.306 |
Net margin | -922.66% | -21.28% | -6.63% | 3.93% | 1.94% | 7.19% | 1.47% | 4.12% | 1.34% | -1.12% | 5.98% | 7.16% | 11.49% | 5.38% | 12.23% |
EPS 2 | -2.260 | -0.1000 | -0.0300 | 0.0200 | 0.0100 | 0.0400 | 0.0100 | 0.0200 | 0.0100 | -0.0100 | 0.0149 | 0.0241 | 0.0422 | 0.0277 | 0.0435 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/22 | 5/12/22 | 8/9/22 | 11/10/22 | 3/7/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/12/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 64.4 | 62.5 | 35.6 | 54.1 | 91.2 | 133 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.33 | 6.23 | 16 | 24.3 | 45.3 | - |
ROE (net income / shareholders' equity) | - | - | -15.1% | 20.3% | 32.6% | 29.3% | 26% |
ROA (Net income/ Total Assets) | - | - | - | 10.3% | 23.9% | 25.8% | - |
Assets 1 | - | - | - | 58.27 | 52.03 | 95.91 | - |
Book Value Per Share 2 | - | 0.4900 | 0.5700 | 0.4200 | 0.8000 | 1.250 | 1.370 |
Cash Flow per Share 2 | - | -0 | 0.1700 | 0.2000 | 0.2500 | 0.3100 | - |
Capex 1 | - | 8.01 | 7.93 | 9.67 | 9.61 | 10.5 | 13.2 |
Capex / Sales | - | 7.17% | 5.28% | 5.54% | 4.68% | 4.33% | 4.67% |
Announcement Date | 9/17/21 | 3/24/22 | 3/7/23 | 3/12/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.02% | 856M | |
+14.49% | 3,200B | |
+11.31% | 87.43B | |
+7.52% | 79.69B | |
-11.83% | 56.79B | |
+23.30% | 47.14B | |
+32.46% | 46.62B | |
-26.51% | 45.5B | |
+81.90% | 42.31B | |
-6.42% | 25.81B |
- Stock Market
- Equities
- ENFN Stock
- Financials Enfusion, Inc.